Bristol-Myers Squibb - Corporate Responsibility - Requests For Proposls


	Patient Assistance Programs
	Fighting AIDS in Africa
	Bristol-Myers Squibb Foundation & Corporate Philanthropy
	Product Integrity
	Sustainability: Our Plan for Responsible Growth
	Environment, Health & Safety Policy
	Medical Education Grants And Charitable Contributions
	Clinical Outcomes And Research Grants
	Position On Key Issues

» BMS.com Home » Corporate Responsibility » Requests For Proposls - Neuroscience

BMS is requesting proposals for Independent Medical Education programs in the following disease areas:

Schizophrenia/Bipolar Disorder
Major Depressive Disorders

Proposals should address the educational needs of physicians, nurses and pharmacists in the United States. If your proposal also addresses educational needs of physicians, nurses and pharmacists outside of the U.S., please include suggestions for extending the program.

Although proposals including any method of education will be considered, the following educational modalities are of particular interest:

Online
Live Presentations
Journal Supplement
Satellite Broadcasts

All responses must be received no later than eight weeks prior to the start date of this proposed program. In addition, responses must be received by the first Wednesday of the month in order to be eligible for review during that month.

Click here to continue >>

[Top Page] [Search] [Index] [Contact] [Home]

Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.